Spironolactone for Hair Loss in Women: The Off-Label Option Explained

The comment thread runs to several hundred replies. A woman in her thirties has posted a photo of her widening part, explains that her dermatologist has just suggested a tablet usually given for blood pressure, and asks the internet whether she is about to grow a beard. As of September 2026, that thread is one of dozens like it, and short-form videos from dermatologists explaining the same prescription are collecting millions of views. Search interest in spironolactone hair loss has climbed with them.

The medicine itself is not new. What is new is the conversation: a fresh wave of review articles summarizing two decades of small studies, growing interest in oral and topical alternatives to the usual foam, and a generation of women who would rather read the evidence than accept thinning hair as inevitable.

So let us read it together, including the parts the videos skip: what the studies actually measured, who was in them, and where the gaps still are.

What changed recently: why spironolactone hair loss is trending now

Spironolactone has been on pharmacy shelves since 1960, when it was first approved in the United States for fluid retention and later for high blood pressure, heart failure and a hormone condition called primary hyperaldosteronism. MedlinePlus still lists those as its approved uses. Hair loss is nowhere on that list, which is exactly why the current surge of interest deserves a calm explanation rather than a hot take.

Three things have converged. First, the evidence base has been tidied up. A 2005 Australian study of 80 women was for years the most quoted paper; a 2015 retrospective review of 166 women and a 2020 review of 79 women added weight, and a 2022 systematic review pooled 12 studies covering more than 600 patients. None of these is a large placebo-controlled trial, but together they gave dermatologists a clearer picture, and Harvard Health now lists spironolactone among the off-label options a clinician may discuss for female pattern hair loss.

Second, the only medicine approved specifically for women’s pattern hair loss in the United States remains topical minoxidil, as Mayo Clinic notes. Women who find the foam messy, irritating or simply not enough have gone looking for what else exists, and spironolactone is usually the next name they meet.

Third, social platforms have turned a quiet clinic conversation into a public one. Dermatologists posting explainers, forum members sharing month-by-month photos, and a parallel rush of interest in compounded topical versions have pushed the drug into trending territory. Some of what circulates is accurate. Some of it is not, and we will separate the two.

What is spironolactone, and why would a blood pressure medicine affect hair?

Spironolactone is a potassium-sparing diuretic, meaning a tablet that helps the kidneys shed excess salt and water while holding on to potassium. It does this by blocking aldosterone, a hormone that tells the kidneys to retain sodium. That is the job it was designed for, and the reason it appears in heart failure guidelines.

The hair story is a side effect that became a feature. Spironolactone’s molecular shape lets it sit in the androgen receptor, the docking site through which male-pattern hormones such as testosterone and dihydrotestosterone (DHT) send their signals to cells. When the receptor is occupied by spironolactone, the hormone cannot deliver its message. The drug also modestly reduces androgen production in the ovaries and adrenal glands. In pharmacology this is called an antiandrogen effect, and it is the same property that led dermatologists to use spironolactone for adult acne and for hirsutism, the medical term for excess facial or body hair in women.

Why does blocking androgens matter for scalp hair? In genetically susceptible follicles, androgen signaling gradually shrinks the follicle, a process called miniaturization. Each new hair grows finer and shorter than the last, until the strand is a barely visible wisp. Interrupt the signal and, in theory, the shrinking stops and some follicles recover.

Two caveats follow from that mechanism. Because the effect works through hormones, it is only relevant to pattern hair loss, not to shedding caused by thyroid disease, iron deficiency or a stressful illness. And because it dampens male-pattern hormones, it is used almost exclusively in women; in men the same action would cause unwanted breast tissue growth and other feminizing effects, so it is not a treatment for male pattern baldness.

Female pattern hair loss explained: what is actually happening on the scalp

Female pattern hair loss, also called androgenetic alopecia, is the most common cause of thinning in women. Cleveland Clinic and Harvard Health both put it at roughly one in three women over a lifetime, with prevalence rising after menopause. It rarely produces the receding hairline or bald crown seen in men. Instead the central part widens, the ponytail feels thinner, and the scalp becomes visible under bright light, while the hair at the front edge is usually preserved.

Every scalp hair cycles through three phases: anagen, the growth phase that normally lasts two to seven years; catagen, a brief transition; and telogen, a resting phase of around three months before the hair falls out and the follicle starts again. In pattern hair loss, anagen shortens with each cycle and the follicle miniaturizes, so a strand that once grew long and thick is replaced by one that is shorter and finer. Nothing is wrong with the number of follicles; the problem is the quality of hair each one produces.

Genetics load the dice, and hormones roll them. Many women with pattern hair loss have entirely normal blood androgen levels; their follicles are simply more sensitive to ordinary amounts. A smaller group has measurably raised androgens, often with polycystic ovary syndrome (PCOS), a hormonal condition that can also bring irregular periods, acne and hirsutism. That distinction matters when a clinician weighs spironolactone, because the drug makes the most biological sense where androgen signaling is clearly part of the picture.

One more detail worth knowing: pattern loss and telogen effluvium, the diffuse shedding that follows illness, childbirth, rapid weight loss or severe stress, often coexist. A clinician will usually want blood tests for iron stores, thyroid function and sometimes vitamin D before attributing everything to hormones.

What the evidence actually says about spironolactone for female pattern hair loss

Here is the honest grading. The best-known data are observational, meaning researchers followed women who were already taking the drug rather than randomly assigning them to it or a placebo. That design can show whether people tend to improve; it cannot prove the medicine caused the improvement, and it tends to flatter treatments because women who do well keep coming back.

The 2005 Australian study followed 80 women for a year on spironolactone or a related antiandrogen. Around 44 percent showed regrowth, another 44 percent held steady, and about 12 percent kept losing hair. The 2015 review of 166 women found stabilization or improvement in roughly 74 percent, judged largely by patient report and clinician assessment. The 2020 review of 79 women reached a near-identical 74 percent, although many were also using minoxidil, which muddies attribution. The 2022 systematic review that pooled these and other studies concluded that spironolactone appears effective and generally well tolerated, and then said plainly what every honest reader should hear: randomized controlled trials are lacking.

Randomized evidence, where it exists, is small. A 2018 open-label study of 100 women combined low-dose oral minoxidil with spironolactone and reported improved hair density scores and reduced shedding at a year, but with no comparison group. A handful of tiny trials have tested topical spironolactone against topical minoxidil, with encouraging but preliminary results.

In plain terms: moderate-quality observational evidence and expert consensus support spironolactone as a reasonable option for women with pattern hair loss, particularly when minoxidil alone is not enough or when androgen excess is suspected. High-quality trial evidence of the kind that underpins minoxidil’s approval does not yet exist. Dermatologists prescribe it anyway, because the mechanism is sound, the long safety record is reassuring, and the alternatives are few. That is a defensible clinical judgment, not a settled scientific fact.

Is spironolactone better than minoxidil? Spironolactone vs minoxidil, honestly compared

They are not really rivals. Minoxidil and spironolactone work on different parts of the problem, and in practice dermatologists frequently use them together.

Minoxidil is a vasodilator, a medicine that widens blood vessels, and its effect on hair is thought to come from prolonging the anagen growth phase and enlarging miniaturized follicles. It does not touch hormones. Topical minoxidil has randomized, placebo-controlled trials behind it, which is why it carries regulatory approval for women. Mayo Clinic describes it as the first-line choice, with visible results taking at least six months and continued use needed to maintain them. Oral minoxidil in low doses has become popular among dermatologists in recent years; its use for hair is also off-label, and its evidence is largely observational, much like spironolactone’s.

Spironolactone, by contrast, addresses the hormonal driver. It makes most sense when the follicles’ androgen sensitivity is the dominant mechanism, when a woman also has acne or hirsutism, or when minoxidil has slowed loss but not enough. It will not help someone whose shedding is caused by iron deficiency or thyroid disease, and it is not appropriate in pregnancy.

So which is better? For a woman with straightforward pattern loss and no other hormonal signs, the stronger evidence sits with minoxidil, and most clinicians would start there. For a woman with signs of androgen excess, or one who has given minoxidil a fair year without satisfaction, adding spironolactone is a well-established next step. The combination, in the studies that exist, generally outperforms either alone, though a formal head-to-head trial has not been done.

The decision about which to use, in what order, belongs to the treating clinician, who can match the mechanism to the woman in front of them.

Treatment options for female pattern hair loss at a glance

The table below summarizes where each commonly discussed option stands, using the evidence grading that medical reviewers apply: randomized controlled trials (RCTs) are the strongest, observational studies are next, and expert opinion is the weakest. Regulatory status refers to the United States unless noted.

Option	How it works	Strength of evidence	Regulatory status for women’s hair loss	Key cautions
Topical minoxidil	Prolongs growth phase, enlarges follicles	Multiple RCTs	Approved	Early shedding, scalp irritation, needs ongoing use
Oral minoxidil (low dose)	Same mechanism, taken by mouth	Observational studies, small trials	Off-label	Unwanted facial or body hair, fluid retention, dizziness
Oral spironolactone	Blocks androgen receptor, lowers androgen production	Observational studies, one systematic review, no large RCT	Off-label	Menstrual changes, breast tenderness, potassium monitoring, not in pregnancy
Topical spironolactone	Local androgen blockade on the scalp	A few small trials	Not approved; compounded only, not for self-use	Limited safety and absorption data
Finasteride (oral)	Blocks conversion of testosterone to DHT	Mixed small trials in women	Off-label in women	Not in pregnancy or women who could become pregnant
Low-level laser devices	Light energy thought to stimulate follicles	Several small RCTs	Device cleared	Modest effect, cost of time and consistency
Platelet-rich plasma injections	Growth factors from own blood injected into scalp	Small, heterogeneous trials	Procedure, no approval pathway	Variable protocols, repeated sessions

Two patterns jump out. Only one medicine has the full weight of randomized trials behind it, and everything else sits one or two rungs lower. That does not make the other options worthless; it means expectations should be scaled to the evidence, and that a clinician’s experience carries more weight when the data are thin.

What is a major side effect of spironolactone? Spironolactone side effects women should know

The side effect that worries pharmacologists most is hyperkalemia, a potassium level in the blood that is too high. Potassium controls the electrical rhythm of the heart, and a serious excess can cause dangerous heart rhythm disturbances. Because spironolactone deliberately stops the kidneys from losing potassium, that risk is built into the drug. In older patients with heart failure or kidney impairment it is a genuine and well-documented concern, which is why the NHS and MedlinePlus both emphasize blood tests.

In the women who typically receive spironolactone for hair loss, young or middle-aged with healthy kidneys, the picture is calmer. Several dermatology studies have questioned whether routine potassium checks are even necessary in healthy young women, because clinically meaningful rises were so rare. Most clinicians still check at baseline and in the first weeks, then as they judge appropriate. That is their call, not yours.

The side effects women actually notice are different. Menstrual irregularity is the most common complaint in the hair loss studies: periods may arrive early, late or more often, or spotting may appear between cycles. Breast tenderness or mild enlargement follows, a direct consequence of shifting the hormone balance. Dizziness or light-headedness on standing reflects the blood-pressure-lowering action and is more noticeable in women whose pressure was already low. Increased urination, fatigue, headache and dry skin round out the usual list.

Less common effects include low sodium, stomach upset and, rarely, a drop in libido. Spironolactone also interacts with other medicines that raise potassium, including certain blood pressure drugs, potassium supplements and some over-the-counter anti-inflammatory painkillers; a clinician needs the full list of what you take.

Most of these effects are mild and settle or are managed by the prescriber. Report them rather than quietly stopping; abrupt changes to any prescribed medicine should go through the person who prescribed it.

Who should not take spironolactone for hair loss?

Pregnancy sits at the top of the list. Because spironolactone blocks androgens, animal studies showed it can interfere with the normal development of male fetuses. Human data are limited, but no clinician will prescribe it to a woman who is pregnant or trying to conceive, and reliable contraception is a standard condition of treatment for women who could become pregnant. If pregnancy is discovered during treatment, the prescriber needs to know straight away.

Kidney disease comes next. The kidneys are where spironolactone acts and where potassium is cleared, so reduced kidney function sharply increases the risk of hyperkalemia. Addison’s disease, a condition in which the adrenal glands fail, and any existing high potassium level are also reasons to avoid it. Women taking other potassium-raising medicines, including ACE inhibitors and angiotensin receptor blockers used for blood pressure, need particularly careful review.

Breastfeeding is a grey area; small amounts of the drug’s breakdown products appear in breast milk, and advice varies, so this is a conversation for the prescriber and, if relevant, the pediatric team.

A history of breast cancer deserves honest discussion rather than a flat prohibition. Early rodent studies at very high doses raised a theoretical concern, and the product labeling still carries a caution. Large observational studies in humans, including several cohorts covering tens of thousands of women, have not found an increased breast cancer risk. Most dermatologists consider the human data reassuring, but a woman with a personal history will want her oncologist involved.

Finally, low blood pressure is a practical limiter. A woman who already feels faint when she stands up may find spironolactone’s pressure-lowering effect hard to live with, and her clinician may prefer a different route.

How long does spironolactone take to work for hair loss?

Longer than anyone wants. Hair grows at roughly one centimeter a month, and a follicle that has just been released from androgen signaling still has to finish its current cycle, rest, and then produce a new, hopefully thicker strand. That biology sets the timetable, and no medicine shortcuts it.

In the published studies, the earliest change women reported was reduced shedding, often in the first three to four months. Visible improvement in density, if it came, typically appeared between six and twelve months, and the Australian study that followed women for a full year found some were still improving at the end. Dermatologists therefore ask for a minimum of six months before judging whether spironolactone is doing anything, and prefer twelve.

Expectation management matters here more than almost anywhere else in dermatology. Across the observational data, the most common outcome was stabilization: the part stopped widening, the ponytail stopped shrinking, and the slow slide was halted. Regrowth to a previous, fuller state happened in a minority. For a progressive condition, stopping progression is a meaningful win, but it is not the before-and-after transformation that social media favors.

Photographs help. A clinician will often take standardized images of the part line at the start and at six-month intervals, because memory is a poor judge of gradual change and daily mirror checks make everything look the same. A simple home version, the same spot, the same lighting, the same hairstyle, taken monthly, gives you and your prescriber something concrete to compare.

What happens if you stop? Follicles that were being protected from androgens become exposed again, and the pattern loss resumes over subsequent months. Spironolactone manages the process while it is taken; it does not reset the underlying sensitivity. Any decision to continue, pause or stop should go through the prescriber.

Topical spironolactone for hair loss: promising idea, thin evidence

The appeal is obvious. If the point is to block androgens in scalp follicles, why not put the drug on the scalp and spare the rest of the body the menstrual changes, breast tenderness and dizziness? A topical version could, in theory, also be used by women for whom oral treatment is unsuitable.

The reality, as of September 2026, is a small stack of studies rather than a settled treatment. A few trials, mostly from the past decade and each involving a few dozen participants, have compared a topical spironolactone preparation with topical minoxidil or with a combination of the two. Results have generally favored the combination and found topical spironolactone roughly comparable to minoxidil in some measures, with less systemic absorption. Those are encouraging signals. They are also short, small and methodologically varied, and the 2022 systematic review treated them as preliminary.

Regulatory status is the part that gets lost in viral posts. No topical spironolactone product is approved by the FDA, the UK’s regulator or the European Medicines Agency for any use. What exists is compounded, meaning prepared individually by a pharmacy to a prescriber’s specification, outside the approval process that tests a product’s absorption, stability and safety. Compounded preparations are legitimate when a licensed clinician prescribes them for an individual patient; they are not consumer products, and anything sold online as topical spironolactone without a prescription is outside the regulated system and should be left alone.

Unanswered questions remain about how much drug penetrates the scalp, whether a meaningful amount reaches the bloodstream, and how it behaves in pregnancy. Until better trials answer them, topical spironolactone belongs in the category of options a dermatologist may discuss, with eyes open about the evidence, rather than one anyone should seek out independently.

Can spironolactone help with perimenopause symptoms and hair thinning?

Perimenopause, the years of hormonal fluctuation before periods stop, is when many women first notice their part widening. Estrogen declines, androgens decline more slowly, and the ratio tilts in a direction that susceptible follicles dislike. It is therefore natural to ask whether a medicine that blocks androgens could help with the whole perimenopausal package.

The answer splits cleanly. Spironolactone does nothing for the classic symptoms driven by falling estrogen: hot flashes, night sweats, vaginal dryness, sleep disruption and mood changes. Those respond to menopausal hormone therapy and to specific non-hormonal medicines, decisions that sit with a woman’s own doctor and are well covered by NHS and Mayo Clinic guidance. Spironolactone is not a substitute for any of them and is not a menopause treatment.

Where it may play a role is the androgen-flavored corner of midlife: pattern hair thinning, adult acne along the jaw, and new facial hair. Dermatologists do prescribe spironolactone to perimenopausal and postmenopausal women for hair loss, and the observational studies included women across this age range. Some clinicians combine it with minoxidil in this group; others reach for it when a woman cannot or prefers not to use hormone therapy.

Two practical notes for this age group. Blood pressure often rises in midlife, and spironolactone’s pressure-lowering effect may be a welcome bonus or an unwanted complication depending on where a woman starts; her clinician will factor that in. And because the risk of hyperkalemia rises with age and with kidney function, monitoring tends to be taken more seriously in women over fifty than in women in their twenties.

If menopausal symptoms are the main concern, start that conversation with a clinician first. Hair can be part of the same discussion, but it should not drive the choice of a medicine that was never designed for the rest of the picture.

What is the best treatment for female hair loss?

The best treatment is the one that matches the cause, which is a less satisfying answer than a product name but the only accurate one.

Diagnosis comes first. A clinician looking at thinning hair will ask about the pattern and timing, examine the scalp, and often order blood tests: ferritin to measure iron stores, thyroid function, and sometimes hormone levels if PCOS is suspected. Telogen effluvium after illness or childbirth usually recovers on its own within months. Iron deficiency responds to correcting the deficiency. Scarring alopecias, a group of conditions in which inflammation permanently destroys follicles, need entirely different treatment and are urgent. Spironolactone helps none of these.

For confirmed female pattern hair loss, the evidence hierarchy is clear. Topical minoxidil is first-line because it has the randomized trials. If a woman has signs of androgen excess, or if minoxidil alone has not done enough after a fair trial, adding an antiandrogen such as spironolactone is the standard next move, supported by observational data and wide clinical experience. Low-dose oral minoxidil is increasingly used in a similar position. Beyond medicines, low-level laser devices have modest trial support, platelet-rich plasma has mixed evidence, and hair transplantation can redistribute follicles for women with sufficient donor hair, though it does not stop the underlying process.

Harvard Health makes a point worth repeating: results from any of these are gradual and partial, and the most realistic goal is to keep the hair you have while regaining some of what was lost. Combination approaches generally outperform single agents. A clinician who says that out loud, rather than promising a full head of hair, is giving you accurate medicine.

Which combination is best for you depends on your age, plans for pregnancy, blood pressure, other medicines and preferences, and that is precisely why the decision belongs in a consultation rather than a comment thread.

Common myths about spironolactone and hair loss, corrected

Myth: spironolactone makes women grow facial hair. The opposite is true. By blocking androgens it reduces unwanted facial and body hair, which is why it has long been used for hirsutism. The medicine that can cause new facial hair in women is oral minoxidil, and the two are sometimes confused because they are prescribed together.

Myth: it is a hormone, like the pill. Spironolactone is not a hormone and contains no estrogen or progesterone. It is a diuretic that happens to block hormone receptors. It is also not a contraceptive, which matters because contraception is usually required while taking it.

Myth: it causes breast cancer. The caution comes from rodent studies at very high doses. Large human cohort studies have not shown an increased risk. Women with a personal history should still discuss it with their oncologist, but the viral framing overstates the evidence.

Myth: results show in a few weeks. Hair biology does not permit it. Reduced shedding may appear within three to four months; density changes take six to twelve. Anyone claiming faster results is describing something other than spironolactone’s effect.

Myth: it works for everyone with thinning hair. It only addresses androgen-driven pattern loss. Shedding from iron deficiency, thyroid disease, illness or scarring conditions will not respond, and a wrong diagnosis wastes a year.

Myth: the topical version is approved and safer. No topical spironolactone is approved anywhere. Early trials are encouraging but small, and products offered without a prescription are outside the regulated system.

Myth: once hair regrows, you can stop. The protection lasts while the drug is taken. Stopping allows the pattern process to resume, which is why any change should go through the prescriber rather than happen because a bottle ran out.

When to see a doctor about hair loss or spironolactone side effects

Start with the hair itself. See a clinician, ideally a dermatologist, if your part has visibly widened over months, if your ponytail circumference has shrunk, if shedding has lasted more than six months, or if hair loss arrived alongside acne, irregular periods or new facial hair. Those are signs that a hormonal pattern may be at play and that a proper diagnosis will change what treatment makes sense.

Some hair loss should be seen promptly rather than watched. Patches of loss with redness, scaling, pain, burning or pus can indicate a scarring alopecia or an infection, and follicles destroyed by scarring do not come back. Sudden loss of large amounts of hair, or loss accompanied by weight change, fatigue, palpitations or feeling cold all the time, warrants blood tests for thyroid and iron problems. Hair loss with easy bruising, joint pain or a facial rash needs evaluation for autoimmune conditions.

If you are already taking spironolactone, contact your prescriber without delay for any of the following red flags: muscle weakness, numbness or tingling, an irregular or slow heartbeat, or chest discomfort, since these can signal high potassium; fainting or severe dizziness; very little urine over a day; confusion or extreme drowsiness, which may indicate low sodium; a rash with facial swelling or breathing difficulty, which suggests an allergic reaction; or a positive pregnancy test. Severe symptoms, especially chest pain, fainting or breathing difficulty, are reasons for emergency care, not a routine appointment.

Milder issues deserve a conversation too. Breast tenderness, menstrual changes, light-headedness on standing and fatigue are common, usually manageable, and worth reporting so the prescriber can adjust the plan. Do not stop, pause or change the medicine on your own, and do not combine it with potassium supplements, salt substitutes or new medicines without checking first. Every decision about starting, continuing or ending spironolactone belongs to the clinician who prescribed it and who knows your blood results.

Frequently asked questions

Is spironolactone better than minoxidil for female hair loss?

Neither is simply better; they work differently and are often combined. Topical minoxidil has randomized trials and regulatory approval, so most clinicians start there. Spironolactone addresses the hormonal driver and is typically added when minoxidil is not enough or when acne or hirsutism point to androgen excess. The studies that exist suggest the combination outperforms either alone. Which to use, and in what order, is a decision for your treating clinician.

What is a major side effect of spironolactone?

High potassium, called hyperkalemia, is the side effect clinicians take most seriously because it can disturb heart rhythm. It is uncommon in healthy young women but more likely with kidney problems, older age or certain blood pressure medicines, which is why blood tests are used. The side effects women notice most often are different: irregular periods, breast tenderness, dizziness on standing and more frequent urination.

Can spironolactone be used to manage perimenopause symptoms?

Not the classic ones. Spironolactone does not treat hot flashes, night sweats, vaginal dryness or sleep disruption, which are driven by falling estrogen and need a separate conversation about menopausal hormone therapy or non-hormonal options. It may help the androgen-related changes of midlife, including pattern hair thinning, jawline acne and new facial hair. Any use in perimenopause should be decided with your own clinician.

How long does spironolactone take to work for hair loss?

Expect months, not weeks. Reduced shedding is often the first sign, around three to four months in. Changes in density, where they occur, usually appear between six and twelve months, and some women in published studies were still improving at a year. Dermatologists ask for at least six months before judging the response. Standardized photographs of the part line help track change that mirrors miss.

Does topical spironolactone for hair loss work?

The evidence is early. A few small trials have compared a topical preparation with topical minoxidil and found broadly similar or complementary effects with less absorption into the body. No topical spironolactone product is approved by any regulator; those used in studies or clinics are compounded on an individual prescription. It is an option a dermatologist may discuss, not something to seek out or buy independently.

What are spironolactone side effects women should watch for?

Common and usually mild effects include irregular or more frequent periods, breast tenderness, light-headedness when standing, headache, fatigue and increased urination. Contact your prescriber urgently for muscle weakness, tingling, an irregular heartbeat, fainting, very little urine, confusion or a rash with swelling, which can signal high potassium, low sodium or an allergic reaction. Report milder issues rather than stopping on your own.

What is the best treatment for female hair loss overall?

The treatment that fits the diagnosis. Iron deficiency, thyroid disease and post-illness shedding each need their own approach, and spironolactone helps none of them. For confirmed female pattern hair loss, topical minoxidil is first-line because it has the strongest trial evidence, with an antiandrogen such as spironolactone added when needed. Combination approaches generally do better than single agents, and the realistic goal is preservation plus partial regrowth.

Is spironolactone for female pattern hair loss safe long term?

Its safety record spans more than six decades of use for heart and blood pressure conditions, and dermatology studies following women for years have reported mostly mild, reversible side effects. Large human studies have not shown an increased breast cancer risk despite an older rodent finding. Long-term use still requires periodic review by the prescriber, including blood tests as they judge appropriate, and it is not used in pregnancy.

Do I need to take spironolactone forever to keep my hair?

The benefit lasts while the medicine is taken. Spironolactone shields follicles from androgen signaling but does not change their underlying sensitivity, so stopping allows pattern loss to resume gradually over the following months. Many women continue for years under medical supervision. Any decision to continue, pause or stop should be made with the prescribing clinician rather than on your own.

Can men use spironolactone for hair loss?

No. In men, blocking androgens causes enlarged breast tissue (gynecomastia), reduced libido and other feminizing effects, so oral spironolactone is not used for male pattern baldness. Men with pattern loss have their own evidence-based options, including minoxidil and finasteride, which a clinician can discuss. Spironolactone’s hair loss use is almost entirely confined to women.

References

• MedlinePlus: Spironolactone
• NHS: Spironolactone
• NHS: Hair loss

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.